NCT05230810 2026-03-16Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Criterium, Inc.Phase 1/2 Active not recruiting40 enrolled
NCT04385563 2020-05-13A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3 Unknown338 enrolled